Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm

被引：0
|
作者：
Becker, Pamela S. [1 ]
Medeiros, Bruno C. [2 ]
Stein, Anthony Selwyn [3 ]
Appelbaum, Frederick R. [4 ]
Scott, Bart L. [5 ]
Delaney, Colleen [5 ,6 ]
Othus, Megan
Hendrie, Paul C.
Gardner, Kelda M. [5 ]
Petersdorf, Stephen [7 ]
Pagel, John M.
Walter, Roland B. [5 ]
Parks, Cynthia [1 ]
Estey, Elihu H. [5 ]
机构：
[1] Univ Washington, Div Hematol, Seattle, WA 98195 USA
[2] Stanford Comprehens Canc Ctr, Div Hematol, Stanford, CA USA
[3] City Hope Natl Med Ctr, Hematol & HCT, Duarte, CA USA
[4] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA USA
[5] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
[6] UW, Dept Pediat, Seattle, WA USA
[7] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.3594.3594
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3594
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase II study with decitabine, low-dose cytarabine and G-CSF priming in high-risk myelodysplastic syndromes, refractory/relapsed acute myelogenous leukemia or acute myeloid leukemia in patients with significant comorbidities
    Butera, J.
    Winer, E.
    Wang, C.
    Castillo, J. J.
    Thomas, A. G.
    Safran, H.
    Mega, A. E.
    Colvin, G. A.
    Rathore, B.
    Quesenberry, P. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia
    Zhang, Xueya
    Guo, Xizhe
    ANNALS OF HEMATOLOGY, 2019, 98 (09) : 2223 - 2225
  • [23] Updated Results of a Randomized Phase II Trial of Idarubicin and Cytarabine with Clofarabine or Fludarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia
    Short, Nicholas J.
    Ravandi, Farhad
    Huang, Xuelin
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Daver, Naval
    Khouri, Rita B.
    Borthakur, Gautam
    Jain, Nitin
    Konopleva, Marina
    Estrov, Zeev
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Wierda, William G.
    DiNardo, Courtney D.
    O'Brien, Susan M.
    Shah, Syed
    Pike, Allison
    Brandt, Mark
    Kantarjian, Hagop M.
    Jabbour, Elias J.
    BLOOD, 2016, 128 (22)
  • [24] Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome
    Garcia-Manero, Guillermo
    Tambaro, Francesco Paolo
    Bekele, Nebiyou B.
    Yang, Hui
    Ravandi, Farhad
    Jabbour, Elias
    Borthakur, Gautam
    Kadia, Tapan M.
    Konopleva, Marina Y.
    Faderl, Stefan
    Cortes, Jorge E.
    Brandt, Mark
    Hu, Yumin
    Mccue, Deborah
    Newsome, Willie Mae
    Pierce, Sherry R.
    de Lima, Marcos
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (18) : 2204 - 2210
  • [25] Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
    Jorge E. Cortes
    Florian H. Heidel
    Andrzej Hellmann
    Walter Fiedler
    B. Douglas Smith
    Tadeusz Robak
    Pau Montesinos
    Daniel A. Pollyea
    Pierre DesJardins
    Oliver Ottmann
    Weidong Wendy Ma
    M. Naveed Shaik
    A. Douglas Laird
    Mirjana Zeremski
    Ashleigh O’Connell
    Geoffrey Chan
    Michael Heuser
    Leukemia, 2019, 33 : 379 - 389
  • [26] Idarubicin and Cytarabine Combined with Clofarabine or Fludarabine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: Interim Result of a Phase II Clinical Trial
    Koller, Paul B.
    Sasaki, Koji
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    O'Brien, Susan
    Cortes, Jorge E.
    Kadia, Tapan
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval
    Chahoud, Jad
    Pike, Allison
    Brandt, Mark
    Pierce, Sherry
    Kantarjian, Hagop M.
    Jabbour, Elias
    BLOOD, 2015, 126 (23)
  • [27] Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
    Cortes, Jorge E.
    Heidel, Florian H.
    Hellmann, Andrzej
    Fiedler, Walter
    Smith, B. Douglas
    Robak, Tadeusz
    Montesinos, Pau
    Pollyea, Daniel A.
    DesJardins, Pierre
    Ottmann, Oliver
    Ma, Weidong Wendy
    Shaik, M. Naveed
    Laird, A. Douglas
    Zeremski, Mirjana
    O'Connell, Ashleigh
    Chan, Geoffrey
    Heuser, Michael
    LEUKEMIA, 2019, 33 (02) : 379 - 389
  • [28] Venetoclax plus D-CAG (decitabine, cytarabine, aclarubicin, G-CSF) for elderly or unfit patients with newly diagnosed acute myeloid leukemia: a multicenter, prospective study
    Ma, Hongbing
    Du, Yiwen
    Li, Jianjun
    Rao, Jin
    Guo, Yong
    Yang, Yunfan
    Zhang, Duanzhong
    Wang, Jia
    Liao, Yi
    Gong, Yuping
    ANNALS OF HEMATOLOGY, 2024, : 5315 - 5323
  • [29] A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome
    Wei, Guoqing
    Ni, Wanmao
    Chiao, Jen-wei
    Cai, Zhen
    Huang, He
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2011, 4
  • [30] A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome
    Guoqing Wei
    Wanmao Ni
    Jen-wei Chiao
    Zhen Cai
    He Huang
    Delong Liu
    Journal of Hematology & Oncology, 4
12345